We believe that closing the gaps between academic cancer research and the pharma industry is crucial. That is why we develop academic cancer projects to clinical proof of concept and enable pharma partners to complete the final steps.
We believe that closing the gaps between academic cancer research and the pharma industry is crucial. That is why we develop academic cancer projects to clinical proof of concept and enable pharma partners to complete the final steps.
We are a German biotech company with a distinctive strategy to fight cancer. Our clout relies on each of our individuals' and partners' experience that is combined in teamwork.
We are a German biotech company with a distinctive strategy to fight cancer. Our clout relies on each of our individuals' and partners' experience that is combined in teamwork.
Just like the biotech scene, we are dynamic and constantly evolving. Take part in our journey and follow our latest news:
ORYX to attend CIMT 2024
New Website launched
Prof. Dr. zur Hausen passed away